Retatrutide Crosses 20 Percent Weight Loss in Type 2 Diabetes

People with type 2 diabetes lost an average of 49.6 pounds on the highest dose of Eli Lilly’s retatrutide, a 20.8% drop over 80 weeks. That is the first time a diabetes drug trial has cleared a 20% mean loss.

The 60-pound figure in early recaps came from a heavier subgroup. People who started with a BMI of 35 or higher lost 60.8 pounds, or 23.4%, on 12 mg. Lilly has not asked the FDA to approve the shot and says it will file in the first quarter of 2027.

The High Dose Pushed Most Patients Below Obesity

TRIUMPH-2 randomized 1,152 adults with type 2 diabetes and obesity or overweight to weekly retatrutide at 4 mg, 9 mg, or 12 mg, or to placebo. Mean starting weight was 234.6 pounds. Mean BMI was 38.2. Mean A1C was 7.7%.

Lilly’s headline analysis assumes people stayed on the assigned shot. On that count, the 12 mg group lost an average of 49.6 pounds (20.8%). The 9 mg group lost 45.4 pounds (19.1%). The 4 mg group lost 29.8 pounds (12.7%). Placebo lost 9.3 pounds (4.0%).

TRIUMPH-2 RESULTS AT 80 WEEKS

By week 80, 59.5% of people on 12 mg no longer met the BMI cutoff for obesity. Just over half on that dose, 52.0%, lost at least 20% of starting weight, and 34.9% lost at least 25%.

The phase 3 TRIUMPH-2 results in The Lancet use a stricter count that keeps people who stopped the drug. That treatment-regimen analysis still found an 18.8% mean loss at 12 mg versus 5.1% on placebo. Of 1,152 people assigned a group, 965 (84%) finished the study drug. Enrollment ran from July 11, 2023, to November 1, 2024, at 92 sites in eight countries.

Juan P. Frias, medical director at the Los Angeles Institute for Metabolic Research and a principal investigator, said the two conditions have always been hard to treat together. “In TRIUMPH-2, retatrutide reduced both weight and blood sugar substantially, with more than half of participants no longer qualifying as having obesity and up to 40% reaching an A1C in the normal range,” he said. “Results such as these may change what we set out to achieve with a single therapy for adults living with type 2 diabetes and obesity.”

Type 2 Diabetes Has Always Cut These Losses in Half

The 20.8% mean is the point of the diabetes paper, not a rounding error on the obesity trials. People with type 2 diabetes routinely lose less on the same incretin shots than people who have obesity alone.

High-quality reviews find that less efficacious in patients with diabetes is the pattern across diet, pills, shots, and surgery, and that it is sharpest for incretin drugs. Semaglutide 2.4 mg produced a 9.6% loss in the STEP 2 diabetes trial, against 15.8% over 68 weeks in people without diabetes. Tirzepatide 15 mg produced a 20.9% loss in SURMOUNT-1 (no diabetes) and about 11% to 16% in diabetes trials, depending on the study and the length of follow-up. Those were separate programs, not head-to-head tests.

Insulin resistance makes it easier to store fat. When blood sugar falls, the kidneys stop dumping glucose in urine, so an energy leak closes just as the new drug starts working. Insulin and sulfonylureas, still common background drugs, push the scale the other way. The American Diabetes Association notes that about 90 percent also have obesity or overweight, which is why a diabetes trial that finally clears 20% changes clinic math, not just a press-release ranking.

Even in TRIUMPH-2, a thin slice of people on 9 mg and 12 mg still gained weight, about 2% to 3% in dose-level plots circulating from the paper. That non-response is familiar from tirzepatide clinics. It is now visible inside a trial that otherwise moved the diabetes ceiling.

Glucagon Is the Extra Lever Tirzepatide Does Not Have

Retatrutide is a single weekly peptide that turns on three gut-hormone receptors. Lilly already sells tirzepatide, a dual agonist, as Mounjaro for diabetes and Zepbound for weight. The new molecule adds glucagon.

THE THREE RECEPTORS RETATRUTIDE HITS

• GLP-1: Cuts appetite and slows how fast the stomach empties, the same lever used by semaglutide.
• GIP: Helps insulin release after meals and changes how fat tissue handles fuel, the second lever in tirzepatide.
• Glucagon: Raises resting energy use and speeds fat burn in the liver, the step neither approved shot takes.

Glucagon’s classic job is to raise blood sugar. The design bet is that GLP-1 and GIP insulin effects offset that rise while the extra burn keeps weight moving after appetite suppression plateaus. Mouse work with a glucagon-blocking antibody wiped out the energy-use bump but left food intake intact, which is why Lilly is willing to cannibalize its own dual agonist.

The trade is not free. Gastrointestinal side effects track other incretins. On 12 mg, 33.6% reported diarrhea, 28.0% nausea, 16.8% constipation, and 15.7% vomiting, against 13.2%, 8.0%, 9.4%, and 4.2% on placebo. Dysesthesia, a tingling or odd-skin sensation, reached 7.3% on 12 mg versus 0.7% on placebo. Hypotension was more common on the higher doses. People stopped for side effects at 3.8% (4 mg), 11.6% (9 mg), and 7.7% (12 mg), versus 4.9% on placebo. Seven people died during the trial, two on 4 mg, three on 9 mg, one on 12 mg, and one on placebo. Investigators judged none of the deaths related to treatment.

Dr. Michelle Ponder, an assistant professor of medicine at Duke University School of Medicine who was not involved in the trial, said an A1C of 5.7% means diabetes went into remission. She also said retatrutide may be too strong for some patients with only mild diabetes or slightly elevated weight, who may be better suited to shots already on the market.

Who Still Needs Gastric Bypass?

Dr. Susan Spratt, an endocrinologist and senior medical director for the Population Health Management Office at Duke Health, was not involved in TRIUMPH-2 and does not take money from Lilly. She put the diabetes result next to an operating room, not next to older pills.

It rivals gastric bypass surgery without the surgery.

Dr. Susan Spratt, endocrinologist, Duke Health

That line holds as a clinic reaction. It does not make the two treatments the same. Merged data from the SLEEVEPASS and SM-BOSS randomized trials found Roux-en-Y gastric bypass produced 30.8% total weight loss at one year and 27.2% at five years. TRIUMPH-2’s 20.8% mean in diabetes is the most a medicine trial has shown in that group, and it is still below those surgical averages.

The closer overlap is in people who do not have diabetes. In TRIUMPH-1, published the same day, 2,339 adults with obesity without diabetes lost 28.3% (70.3 pounds) on 12 mg at 80 weeks, 25.9% (64.4 pounds) on 9 mg, and 19.0% (47.2 pounds) on 4 mg. On 12 mg, 65.3% fell below a BMI of 30. A 104-week extension in people who started at a BMI of 35 or higher reached 30.3%, or 85.0 pounds, on 12 mg.

Weight that returns when a shot stops still leaves surgery as the durability option. Real-world GLP-1 series have shown much smaller losses than trials, largely because people quit. A weekly pen that matches bypass only while someone keeps injecting has not replaced a gastric bypass. It has given diabetes clinics a number they could not print before.

Spratt also noted a quieter clinic fact. Many diabetes drugs, including insulin, cause weight gain. “It can be discouraging to manage your diabetes well but gain weight,” she said.

Lilly Sues Six Sellers of Unapproved Copies

The molecule is still a trial drug. Lilly says retatrutide cannot be legally sold or marketed for human use. The FDA has said it cannot be compounded. Copies labeled “for research use only” are already moving through wellness platforms, med spas, and compounding pharmacies.

FROM TRIAL PROGRAM TO COURT DOCKET

1. 2023: The TRIUMPH phase 3 program begins. Lilly later said it enrolled more than 5,800 people across obesity, diabetes, sleep apnea, and knee-pain trials.
2. July 11, 2023: TRIUMPH-2 screening opens. Dosing starts at 2 mg and steps up every four weeks to 4, 9, or 12 mg.
3. May 21, 2026: Lilly reports TRIUMPH-1 obesity topline figures, including the 28.3% and 85.0-pound results.
4. June 6, 2026: TRANSCEND-T2D-1, in 537 adults with recent-onset type 2 diabetes and no other diabetes drugs, shows a 16.8% loss (36.6 pounds) and up to a 2% A1C drop over 40 weeks.
5. August 12, 2026: Lilly files six lawsuits against Aesthetic Envy Cosmetic Centers, Astra LLC, Legendary Peptides, Striker Pharmacy, Texas Peptides, and Lone Star Peptide Co.
6. September 29, 2026: TRIUMPH-2 appears in The Lancet and is presented at the European Association for the Study of Diabetes meeting in Milan. TRIUMPH-1 appears in the New England Journal of Medicine.
7. First quarter of 2027: Lilly plans to submit a Biologics License Application to the FDA.

Lilly said it had referred more than 200 people and entities to the FDA, the Justice Department, state attorneys general, and police, and had flagged more than 14,000 websites, ads, and listings in more than 100 countries. A separate fight over whether retatrutide should be regulated as a biologic or a traditional drug will decide how long exclusivity lasts and how tightly compounding stays shut.

Until a license exists, every vial outside a trial is an unapproved product. The demand is already behaving as if the license were here.

Two in Five Reached a Normal A1C

Weight was the primary endpoint. Blood sugar and heart-risk markers moved with it. From a 7.7% baseline, A1C fell 1.4% on 4 mg, 1.6% on 9 mg, and 1.5% on 12 mg, versus 0.2% on placebo. The share who reached an A1C of 6.5% or lower was 73.1%, 79.2%, and 79.0% on the three doses, versus 26.3% on placebo.

An A1C below 5.7% sits under the cutoffs for both diabetes and prediabetes. That bar was cleared by 28.4% on 4 mg, 40.0% on 9 mg, and 39.3% on 12 mg, versus 4.4% on placebo.

12 MG CARDIOMETABOLIC CHANGES

• Triglycerides: Down 39.5% on average at the highest dose.
• Non-HDL cholesterol: Down 19.6%.
• Systolic blood pressure: Down 10.8 mm Hg.
• Waist: Down 6.7 inches (16.9 cm); high-sensitivity C-reactive protein down 58.3%.

TRIUMPH-1 also measured knee osteoarthritis pain and obstructive sleep apnea as primary outcomes in those subgroups and found both improved. Lilly said extra sleep-apnea results from inside TRIUMPH-2 will come at a later meeting. A dedicated heart-and-kidney outcomes trial, TRIUMPH-Outcomes, is still running and is not due for years.

Kenneth Custer, president of Lilly Cardiometabolic Health, said the company now sees retatrutide as a future option for people living with both type 2 diabetes and obesity. The 4 mg obesity-trial dose, which used only one step-up, still produced a 19.0% loss with fewer people stopping for side effects than placebo, which is the practical door for patients Ponder worries will be over-treated at 12 mg.

Lilly plans a biologics application in the first quarter of 2027. Until then retatrutide is not a licensed medicine, and the copies already on spa menus are not the drug in these papers. The diabetes trial did something older GLP-1 shots never did for this group: it printed a 20% mean and moved most people on 12 mg out of the obesity BMI range.

Frequently Asked Questions

What is retatrutide and how does it work?

Retatrutide is a once-weekly injectable peptide, also called LY3437943, that activates receptors for GIP, GLP-1, and glucagon in one molecule. People in TRIUMPH-2 gave themselves the shot and started at 2 mg, with the dose raised every four weeks until they reached 4 mg, 9 mg, or 12 mg. It is not approved for any use, and Lilly is also testing it for knee osteoarthritis pain, sleep apnea, chronic low back pain, liver fat disease, and heart and kidney outcomes.

How much weight did people with type 2 diabetes lose on each retatrutide dose?

On Lilly’s stay-on-treatment analysis, mean loss at 80 weeks was 29.8 pounds (12.7%) on 4 mg, 45.4 pounds (19.1%) on 9 mg, and 49.6 pounds (20.8%) on 12 mg, from a 234.6-pound baseline. Among people whose starting BMI was 35 or higher, the 12 mg mean was 60.8 pounds (23.4%). The share who lost at least 15% was 36.6%, 62.2%, and 67.0% on the three doses, versus 6.4% on placebo.

Why do people with type 2 diabetes lose less weight on GLP-1 drugs?

Insulin resistance, high insulin levels, and diabetes drugs that cause gain (insulin, sulfonylureas) all make fat harder to shed. When a new shot lowers blood sugar, the kidneys also stop spilling glucose, which closes a calorie leak that had been masking intake. Median diabetes duration in TRIUMPH-2 was 5.6 years, median obesity duration was 21 years, and 92% of people were already on oral diabetes drugs, including metformin, SGLT2 inhibitors, and sulfonylureas.

What side effects did retatrutide cause in the TRIUMPH-2 trial?

The most common were diarrhea, nausea, constipation, decreased appetite, and vomiting, mostly mild to moderate and mostly during dose increases. Decreased appetite was reported by 5.8%, 12.3%, and 17.1% on 4, 9, and 12 mg, versus 4.5% on placebo. Urinary tract infections were 3.8%, 6.3%, and 8.0% versus 6.6% on placebo. Permanent stops for side effects or death were 4% on 4 mg, 12% on 9 mg, 8% on 12 mg, and 5% on placebo in the Lancet accounting, which includes deaths in that tally.

How does retatrutide differ from tirzepatide?

Tirzepatide hits GIP and GLP-1 receptors. Retatrutide adds glucagon-receptor activity, which is meant to raise energy use and clear liver fat rather than only cut intake. There is no completed head-to-head trial. A separate 80-week study, TRANSCEND-T2D-2, is testing retatrutide against semaglutide, and TRANSCEND-T2D-3 is testing it with insulin in people who also have chronic kidney disease.

Disclaimer: This article is news reporting and analysis of published clinical-trial results. It is for information only and is not medical advice, a treatment recommendation, or a substitute for care from a licensed clinician. It does not tell anyone to start, stop, switch, or compound any diabetes or weight-loss medicine, including retatrutide, tirzepatide, or semaglutide. Speak with a physician or endocrinologist who knows your history before changing therapy, and do not buy unapproved peptides sold as research chemicals. Figures and regulatory status reflect the trial papers and company statements available on September 29, 2026, and both the numbers in practice and the FDA timeline can change.